EORTC abstracts selected at ESMO 2020 Virtual Congress

5 EORTC abstracts were selected for ESMO 2020 that will take place virtually from 19 until 21 September 2020.

On-Demand Mini Oral Sessions

Mini Oral Session-Sarcoma

A new benchmark for designing phase II trials for advanced or metastatic leiomyosarcoma (LMS) patients using progression free survival (PFS) as primary endpoint – an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis

  • Presentation Number:1628MO
  • Date: 18 September 2020
  • Speaker: Georgios Kantidakis (Brussels, Belgium)

First-line chemotherapy (CT) in advanced well-differentiated/ dedifferentiated liposarcoma (WD/DD LPS): an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis

  • Presentation Number: 1629MO
  • Date: 18 September 2020
  • Speaker: Silvia Stacchiotti

Mini Oral Session – Non-metastatic NSCLC and other thoracic malignancies

LATE BREAKING ABSTRACT: REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer

  • Presentation Number: LBA85
  • Date: 18 September 2020
  • Speaker: Benjamin Besse (Villejuif, CEDEX, France)

Proffered Paper Session

Proffered Paper Session: Melanoma and Other Skin Cancers

LATE BREAKING ABSTRACT: Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase 3 trial

  • Presentation Number: LBA46
  • Date: 19 September 2020
  • Lecture Time: 17:16 – 17:28
  • Speaker: Alexander M. Eggermont (Utrecht, Netherlands)

Poster display session

Nintedanib (BIBF1120) after first line therapy in progressive medullary thyroid cancer: a multicenter EORTC prospective randomized double-blind phase II study (NCT01788982)

  • Presentation Number: 1919P
  • Date: 17 September 2020
  • Speaker: Kate Newbold (Sutton, United Kingdom)

For more information, visit ESMO 2020 online programme.

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023